[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Polish Mother Memorial Hospital Research Institute\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":116},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,70,92],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100584441","phase-1-use-of-intranasal-midazolam-to-reduce-stress-and-procedural-pain-in-premature-infants-during-routine-rop-examination-100584441",false,"NCT06889376","Use of Intranasal Midazolam to Reduce Stress and Procedural Pain in Premature Infants During Routine ROP Examination.","The Use of Intranasal Sedation With Midazolam to Reduce Stress, Discomfort and Procedural Pain in Preterm Newborns and Infants During Routine ROP Screening","Inclusion Criteria:\n\n* Newborns qualified for ophthalmologic screening examination to detect retinopathy of prematurity (ROP):\n\n  a. Newborns\u002Finfants born before the 32 weeks of gestation and\u002For with a birth weight \\\u003C1500 g.\n* Obtaining informed consent from a parent\u002Flegal guardian.\n\nExclusion Criteria:\n\n* Newborns\u002Finfants not qualified for screening ophthalmologic examination (ROP).\n* Newborns\u002Finfants clinically unstable, with respiratory disorders\u002Fcardiovascular instability before the ophthalmologic examination.\n* Newborns\u002Finfants with congenital developmental defects.\n* Newborns\u002Finfants receiving analgesic\u002Fsedative medications for other reasons.","ALL","30 Weeks",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","The goal of this study is to learn about the safety and effectiveness of intranasal midazolam in newborns and infants born prematurely, undergoing Retinopathy of Prematurity (ROP) screening.\n\nThe main question it aims to answer is:\n\n• Does use of intranasal midazolam is a safe, quick, non-invasive medication, that reduces the pain, stress, discomfort, and other complications in patients undergoing ROP screening?\n\nResearchers will compare the intervention group with a comparison group of the patients who will receive routine comfort care.",[26],"Drug Safety",[28,29,30],"intranasal midazolam","ROP screening","Premature infants","NOT_YET_RECRUITING","2025-03-16",{"date":34,"type":35},"2025-03-21","ACTUAL",{"date":37,"type":20},"2025-03-24",{"date":39,"type":20},"2025-07-06",{"name":41,"class":42},"Polish Mother Memorial Hospital Research Institute","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":43},"100582105","pmmhri-pitavastatin-registry-100582105","NCT06858982","PMMHRI-Pitavastatin Registry","The Polish Mother's Memorial Hospital Research Institute Pitavastatin Registry","Inclusion Criteria:\n\n* patient takling pitavastatin based on the 2021 Polish Lipid Guidelines\n\nExclusion Criteria:\n\n\\-","18 Years",{"count":53,"type":20},500,"OBSERVATIONAL","The PMMHRI-Pitavastatin Registry is a non-interventional, single-center registry conducted at the Polish Mother's Memorial Hospital Research Institute (PMMHRI). Established in January 2024, the registry enrolls all patients from the Department of Cardiology and Adult Congenital Heart Diseases, the Department of Endocrinology, as well as outpatient cardiology and endocrinology clinics who are prescribed pitavastatin.",[57],"Hypercholesterolemia",[59,60],"hypercholesterolemia","pitavastatin","RECRUITING","2025-02-27",{"date":64,"type":35},"2025-03-05",{"date":66,"type":35},"2024-06-01",{"date":68,"type":20},"2028-12",{"name":41,"class":42},{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":54,"phases":4,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":43},"100563015","the-prevalence-of-hyper-lpa-emia-in-the-pmmhri-lpa-registry-100563015","NCT06610669","The Prevalence of Hyper-Lp(a)-Emia in the PMMHRI-Lp(a) Registry","The Prevalence, Patients' Characteristics, and Hyper-Lp(a)-Emia Risk Factors in the Polish Population. The Polish Mother's Memorial Hospital Research Institute Lipoprotein(a) Registry","Inclusion Criteria:\n\n* measured lipoprotein(a) concentration\n\nExclusion Criteria:\n\n\\-",{"count":78,"type":20},2000,"The PMMHRI-Lp(a)-Registry is a non-interventional, single-center registry conducted in the Polish Mother's Memorial Hospital Research Institute (PMMHRI). The PMMHRI-Lp(a)-Registry was established in January 2022. Since then, all consecutive patients of the Department of Cardiology and Adult Congenital Heart Diseases, Department of Endocrinology, and outpatient cardiology and endocrinology clinics with the measured Lp(a) concentration have been included.",[81],"Lipoprotein(a), Hyper-Lp(a)-Emia",[83],"lipoprotein(a)","2024-09-23",{"date":86,"type":35},"2024-09-24",{"date":88,"type":35},"2022-01-01",{"date":90,"type":20},"2028-06",{"name":41,"class":42},{"id":93,"slug":94,"hasResults":11,"nctId":95,"briefTitle":96,"officialTitle":97,"acronym":98,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":16,"minAge":100,"maxAge":4,"enrollmentInfo":101,"targetDuration":103,"studyType":54,"phases":4,"briefSummary":104,"conditions":105,"keywords":107,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":43},"100560014","pmmhri---familial-hypercholesterolemia-registry-100560014","NCT06571630","PMMHRI - Familial Hypercholesterolemia Registry","Polish Mother's Memorial Hospital Research Institute - Familial Hypercholesterolemia Registry","FH-Registry","Inclusion Criteria:\n\n* FH diagnosis\n\nExclusion Criteria:\n\n\\-","1 Day",{"count":102,"type":20},300,"1 Year","The registry is maintained at the Regional Centre for Rare Diseases, established in 2016, within Polish Mother's Memorial Hospital Research Institute. This facility diagnoses and treats over 80 distinct rare diseases in patients from across the country, including those with phenotypically or genetically confirmed familial hypercholesterolemia (FH).",[106],"Familial Hypercholesterolemia",[106],"2024-08-23",{"date":110,"type":35},"2024-08-26",{"date":112,"type":35},"2018-01-01",{"date":114,"type":20},"2025-12-31",{"name":41,"class":42},""]